Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS